CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 65 enrolled
Drug / intervention
MK-3475drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02085070
NCT02085070Phase 2Completed
CompareCT.gov

A Phase 2 Study of MK-3475 in Patients With Metastatic Melanoma and Non-Small Cell Lung Cancer With Untreated Brain Metastases

Yale University·interventional·Posted Mar 12, 2014·Updated Mar 24, 2021

In Brief

A Phase 2 clinical trial evaluating MK-3475 for Melanoma and 2 related conditions. Completed, enrolled 65 participants across 1 site.

Detailed Summary

The purpose of this trial is to study the activity of MK-3475 in untreated brain metastases from melanoma or non-small cell lung cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma, Non-Small Cell Lung Cancer, Brain Metastases
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 12, 2014
Enrollment StartMar 1, 2014
Primary CompletionFeb 27, 2020
TodayJul 2, 2026
Enrollment to primary: 6.0 yearsPosted 12.3 years ago

Interventions

MK-3475drug

IV MK-3475